{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:45:41Z","timestamp":1776059141047,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04670-3","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T06:33:48Z","timestamp":1772692428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tacrolimus therapy for ulcerative colitis: a retrospective study of factors associated with inducing and maintaining remission"],"prefix":"10.1186","volume":"26","author":[{"given":"Ayumi","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Murasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miki","family":"Koroku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Tokushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousuke","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"4670_CR1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","volume":"29","author":"R Ungaro","year":"2017","unstructured":"Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;29:1756\u201370.","journal-title":"Lancet"},{"key":"4670_CR2","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","volume":"11","author":"M Harbord","year":"2017","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11:769\u201384.","journal-title":"J Crohns Colitis"},{"key":"4670_CR3","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1136\/gut.2005.081794","volume":"55","author":"H Ogata","year":"2006","unstructured":"Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255\u201362.","journal-title":"Gut"},{"key":"4670_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4103\/sjg.sjg_145_21","volume":"27","author":"HN Zhao","year":"2021","unstructured":"Zhao HN, Jiang M, Dai C, et al. The efficacy and safety of infliximab and calcineurin inhibitors in steroid-refractory UC patients: a meta-analysis. Saudi J Gastroenterol. 2021;27:191\u2013200.","journal-title":"Saudi J Gastroenterol"},{"key":"4670_CR5","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","volume":"10","author":"Y Komaki","year":"2016","unstructured":"Komaki Y, Komaki F, Sakurada A, et al. Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J Crohns Colitis. 2016;10:484\u201394.","journal-title":"J Crohns Colitis"},{"key":"4670_CR6","doi-asserted-by":"publisher","first-page":"3162595","DOI":"10.1155\/2016\/3162595","volume":"2016","author":"K Endo","year":"2016","unstructured":"Endo K, Onodera M, Shimosegawa T, et al. A comparison of short- and long-term therapeutic outcomes of infliximab- versus tacrolimus-based strategies for steroid-refractory ulcerative colitis. Gastroenterol Res Pract. 2016;2016:3162595.","journal-title":"Gastroenterol Res Pract"},{"key":"4670_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1136\/gut.50.4.485","volume":"50","author":"AG Fraser","year":"2002","unstructured":"Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 years review. Gut. 2002;50:485\u20139.","journal-title":"Gut"},{"key":"4670_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/pds.926","volume":"13","author":"RB Gearry","year":"2004","unstructured":"Gearry RB, Barclay ML, Chapman BA, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf. 2004;13:563\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4670_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00535-018-1486-7","volume":"53","author":"Y Kakuta","year":"2018","unstructured":"Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study. J Gastroenterol. 2018;53:1065\u201378.","journal-title":"J Gastroenterol"},{"key":"4670_CR10","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841\u20135.","journal-title":"N Engl J Med"},{"key":"4670_CR11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","volume":"317","author":"KW Schroeder","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625\u20139.","journal-title":"N Engl J Med"},{"key":"4670_CR12","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","volume":"145","author":"SP Travis","year":"2013","unstructured":"Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987\u201395.","journal-title":"Gastroenterology"},{"key":"4670_CR13","doi-asserted-by":"publisher","first-page":"175628482091504","DOI":"10.1177\/1756284820915043","volume":"13","author":"SD Rustgi","year":"2020","unstructured":"Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. Therap Adv Gastroenterol. 2020;13:1756284820915043.","journal-title":"Therap Adv Gastroenterol"},{"key":"4670_CR14","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.3748\/wjg.15.4234","volume":"15","author":"PL Lakatos","year":"2009","unstructured":"Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it? World J Gastroenterol. 2009;15:4234\u20139.","journal-title":"World J Gastroenterol"},{"key":"4670_CR15","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1002\/ibd.21318","volume":"16","author":"T Yoshino","year":"2010","unstructured":"Yoshino T, Nakase H, Honzawa Y, et al. Immuno suppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis. 2010;16:2022\u201333.","journal-title":"Inflamm Bowel Dis"},{"key":"4670_CR16","doi-asserted-by":"publisher","first-page":"628157","DOI":"10.1155\/2015\/628157","volume":"2015","author":"A Michielan","year":"2015","unstructured":"Michielan A, D\u02bcInc\u00e0 R. Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. Mediators Inflamm. 2015;2015:628157.","journal-title":"Mediators Inflamm"},{"key":"4670_CR17","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.3390\/molecules26061725","volume":"26","author":"Q Xu","year":"2021","unstructured":"Xu Q, Zhou X, Strober W, et al. Inflammasome regulation: therapeutic potential for inflammatory bowel disease. Molecules. 2021;26:1725.","journal-title":"Molecules"},{"key":"4670_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","volume":"13","author":"S Ben-Horin","year":"2014","unstructured":"Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24\u201330.","journal-title":"Autoimmun Rev"},{"key":"4670_CR19","doi-asserted-by":"publisher","first-page":"175628482210807","DOI":"10.1177\/17562848221080793","volume":"15","author":"A Pudipeddi","year":"2022","unstructured":"Pudipeddi A, Ko Y, Leong RW, et al. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Therap Adv Gastroenterol. 2022;15:17562848221080792.","journal-title":"Therap Adv Gastroenterol"},{"key":"4670_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","volume":"5","author":"D Turner","year":"2007","unstructured":"Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103\u201310.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"4670_CR21","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114:384\u2013413.","journal-title":"Am J Gastroenterol"},{"key":"4670_CR22","first-page":"203","volume":"14","author":"W Ericson-Neilsen","year":"2014","unstructured":"Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203\u20137.","journal-title":"Ochsner J"},{"key":"4670_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.crohns.2008.03.004","volume":"2","author":"M Ferrante","year":"2008","unstructured":"Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis. 2008;2:219\u201325.","journal-title":"J Crohns Colitis"},{"key":"4670_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.5217\/ir.2019.00084","volume":"18","author":"S Mizuno","year":"2020","unstructured":"Mizuno S, Ono K, Mikami Y, et al. 5-aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res. 2020;18:69\u201378.","journal-title":"Intest Res"},{"key":"4670_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/flgastro-2013-100348","volume":"5","author":"LYW Lee","year":"2014","unstructured":"Lee LYW, Gardezi AS, Santharam V, Boyd J, Lanzon-Miller S. Effect of azathioprine intolerance on outcomes of inflammatory bowel disease: a cross-sectional study. Frontline Gastroenterol. 2014;5:40\u20133.","journal-title":"Frontline Gastroenterol"},{"key":"4670_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/ibd\/izac051","volume":"29","author":"SS Dasharathy","year":"2023","unstructured":"Dasharathy SS, Long MD, Lackner JM, et al. Psychological factors associated with adherence to oral treatment in ulcerative colitis. Inflamm Bowel Dis. 2023;29:97\u2013102.","journal-title":"Inflamm Bowel Dis"},{"key":"4670_CR27","doi-asserted-by":"publisher","first-page":"5956316","DOI":"10.1155\/2016\/5956316","volume":"2016","author":"A Ito","year":"2016","unstructured":"Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Tacrolimus for remission induction and maintenance therapy in patients with ulcerative colitis: a retrospective evaluation study. Gastroenterol Res Pract. 2016;2016:5956316.","journal-title":"Gastroenterol Res Pract"},{"key":"4670_CR28","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3390\/jcm9061771","volume":"9","author":"K Haga","year":"2020","unstructured":"Haga K, Shibuya T, Nomura K, et al. Effectiveness and nephrotoxicity of long-term tacrolimus administration in patients with ulcerative colitis. J Clin Med. 2020;9:1771.","journal-title":"J Clin Med"},{"key":"4670_CR29","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1111\/apt.15616","volume":"51","author":"JE Ollech","year":"2020","unstructured":"Ollech JE, Dwadasi S, Rai V, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther. 2020;51:637\u201343.","journal-title":"Aliment Pharmacol Ther"},{"key":"4670_CR30","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","volume":"381","author":"BE Sands","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381:1201\u201314.","journal-title":"N Engl J Med"},{"key":"4670_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/jgh.15667","volume":"37","author":"M Naganuma","year":"2022","unstructured":"Naganuma M, Watanabe K, Motoya S, et al. Potential benefits of immunomodulator use with vedolizumab for maintenance of remission in ulcerative colitis. J Gastroenterol Hepatol. 2022;37:81\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"4670_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1365-2036.2009.04023.x","volume":"30","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Linares PM, McNicholl AG, Mat\u00e9 J, Gomoll\u00f3n F. Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther. 2009;30:126\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"4670_CR33","first-page":"CD007216","volume":"4","author":"M Gordon","year":"2022","unstructured":"Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev. 2022;4:CD007216.","journal-title":"Cochrane Database Syst Rev"},{"key":"4670_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.resinv.2017.01.002","volume":"55","author":"H Tokuda","year":"2017","unstructured":"Tokuda H, Harigai M, Kameda H, et al. Consensus statements for medical practice: biological agents and lung disease [Abridged English translation by the Japanese Respiratory Society]. Respir Investig. 2017;55:229\u201351.","journal-title":"Respir Investig"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04670-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04670-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:56:02Z","timestamp":1776056162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04670-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4670"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04670-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of Tokyo Women\u2019s Medical University (approval number: 2022\u20130143). Written and verbal informed consent was obtained from all patients. All procedures were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}